Market revenue in 2021 | USD 29,412.5 million |
Market revenue in 2030 | USD 54,121.6 million |
Growth rate | 7% (CAGR from 2021 to 2030) |
Largest segment | Mammalian |
Fastest growing segment | Mammalian |
Historical data covered | 2017 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Mammalian, Non-mammalian |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
mammalian was the largest segment with a revenue share of 62.46% in 2021. Horizon Databook has segmented the Global biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
With improvement in outsourced services, biopharmaceuticals industry continues to show surge in number of biopharmaceutical firms opting for contract services. CMOs are making enormous sums of investments for expansion of their manufacturing capabilities. Smaller companies are also expanding their non-GMP facilities. For instance, Biotech pharma UAB installed a 200L single-use bioreactor in its non-GMP process development facility.
Many entities are also observed to add capacity through both internal expansions and acquisitions to fulfill the growing demand for such services. For instance, in December 2014, Fujifilm Diosynth biotechnologies acquired Texas-based Kalon Biotherapeutics with an aim to enhance its vaccine manufacturing capacity.
The company is also engaged in process and analytical development capabilities. As per survey of contract manufacturing organizations (CMOs), manufacturing capacities growing by 7%.The manufacturing capacity for contract manufacturing was estimated to hit 1 million liters in 2015.
Horizon Databook provides a detailed overview of global-level data and insights on the Global biopharmaceutical cmo and cro market , including forecasts for subscribers. This global databook contains high-level insights into Global biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account